ArticleResearch and practice in thrombosis and haemostasis2026
Antithrombotic therapy in lower extremity peripheral artery disease patients with venous thromboembolism: a nationwide cohort study.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antithrombotic therapy (ATT) is recommended for patients with symptomatic lower extremity peripheral arterial disease (PAD). Optimal management of "breakthrough" venous thromboembolic events (VTEs) in these patients remains unclear. This study aims to describe current ATT prescription patterns in PAD patients before, during, and after VTE (treatment) and subsequent clinical outcomes. Methods: Using Dutch nationwide data, this cohort study identified patients with a reimbursement code for PAD between 2013 and 2021. Within this source population, patients with an International Classification of Diseases-10 code for VTE were identified and followed from VTE date until end-of-study date or death, whichever occurred first. ATT prescriptions, determined from pharmacy records, were mapped in 3 timeframes: 3 months before VTE, during VTE treatment, and 4 to 12 months after VTE. Results: Patients with PAD ( Conclusion: Immediate treatment of VTE and long-term ATT use in PAD patients were heterogeneous in our cohort. A substantial proportion of patients had prescriptions for both antiplatelet therapy and anticoagulation during the VTE treatment period. Our findings highlight the need for consensus on this complex clinical dilemma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.